STOCKHOLM - Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX), a biopharmaceutical company specializing in rare diseases, today announced the appointment of Maria Törnsén as President of its North American operations. Törnsén, who brings over two decades of experience in the biopharma sector, will oversee all U.S. operations and report directly to the CEO, Renée Aguiar-Lucander.
Törnsén's career spans significant leadership positions, including her most recent role as Chief Commercial Officer at Passage Bio and prior roles such as SVP General Manager US at Sarepta Therapeutics (NASDAQ:SRPT), VP Global Therapeutic Area Head at Sanofi (EPA:SASY) (NASDAQ:SNY) Genzyme, and VP Head of US Sales at Shire. She succeeds Andrew Udell, who has served since 2020.
The CEO expressed gratitude to Udell for his contributions to the company's early commercial success in the U.S. and welcomed Törnsén's expertise, particularly in commercial growth and profitability within the rare disease market.
Törnsén joins Calliditas following the recent full FDA approval of TARPEYO® (budesonide) delayed-release capsules, intended to slow kidney function loss in patients with primary IgA nephropathy (IgAN) at risk of disease progression. The product has received conditional approval in Europe and China, where it is marketed as Kinpeygo and Nefecon, respectively.
The company is also anticipating top-line results from several Phase 2 clinical trials of setanaxib, its leading candidate from its proprietary NOX platform, in 2024.
Calliditas Therapeutics, headquartered in Stockholm, Sweden, is dedicated to developing and commercializing novel treatments for orphan indications with significant unmet medical needs.
The information in this article is based on a press release statement from Calliditas Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.